Login to Your Account



Arena Scores EMDAC Vote for Lorcaserin, Expanded Contract

By Mari Serebrov
Washington Editor

Friday, May 11, 2012

The second time proved to be a charm for Arena Pharmaceuticals Inc.'s lorcaserin as it sought a vote of confidence from the FDA's Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) in its benefit-risk profile as a weight-loss drug.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription